A Critical Review on the Relevance of Paracetamol for Procedural Pain Management in Neonates by Allegaert, K.M. (Karel)
REVIEW
published: 18 March 2020
doi: 10.3389/fped.2020.00089
Frontiers in Pediatrics | www.frontiersin.org 1 March 2020 | Volume 8 | Article 89
Edited by:
Carlo Bellieni,
University of Siena, Italy
Reviewed by:
Hercília Guimarães,
University of Porto, Portugal
Dick Tibboel,
Erasmus Medical Center, Netherlands
*Correspondence:
Karel Allegaert
karel.allegaert@uzleuven.be
Specialty section:
This article was submitted to
Neonatology,
a section of the journal
Frontiers in Pediatrics
Received: 08 November 2019
Accepted: 21 February 2020
Published: 18 March 2020
Citation:
Allegaert K (2020) A Critical Review on
the Relevance of Paracetamol for
Procedural Pain Management in
Neonates. Front. Pediatr. 8:89.
doi: 10.3389/fped.2020.00089
A Critical Review on the Relevance of
Paracetamol for Procedural Pain
Management in Neonates
Karel Allegaert 1,2,3*
1 Development and Regeneration, KU Leuven, Leuven, Belgium, 2 Pharmaceutical and Pharmacological Sciences, KU
Leuven, Leuven, Belgium, 3 Clinical Pharmacy, Erasmus MC Rotterdam, Rotterdam, Netherlands
Effective and safe pain relief in neonates matters. This is not only because of ethical
constraints or human empathy, but even more because pain treatment is an important
and crucial part of contemporary medical, paramedical, and nursing care to improve
the outcome in neonatal intensive care graduates. Paracetamol (acetaminophen) is likely
one of the pharmacological tools to attain this, with data on prescription practices
suggesting that paracetamol is somehow the “rising star” in neonatal pain management.
Besides very rare topical clinical scenarios like peripartal asphyxia and subsequent whole
body hypothermia or the use of cardiorespiratory support devices, data on paracetamol
pharmacokinetics and metabolism were reported throughout neonatal age or weight
ranges, and we have summarized these data. In this review, we subsequently aimed
to provide the reader with the currently available observations on the use of paracetamol
as analgesic for different pain syndromes (major surgery, minor surgery or trauma,
and procedural pain), with focus on the limitations of paracetamol when prescribed
for neonatal procedural pain management. We hereby intentionally will not discuss
other indications (patent ductus arteriosus and fever) for paracetamol administration
in neonates. Based on the available evidence, paracetamol has opioid-sparing effects
for major pain syndromes, is effective to treat minor to moderate pain syndromes,
but fails for effective procedural pain management in neonates. This efficacy failure for
procedural pain management should stimulate us to continue to search for more effective
interventions, including non-pharmacological interventions and preventive strategies.
Furthermore, there are also upcoming association type of epidemiological studies on
the relation between exposure to analgesics—including paracetamol—and the negative
short- or long-term outcome characteristics (neuro-behavioral, atopy, and fertility).
Consequently and in addition to the search for effective alternatives to prevent or treat
pain, studies on long-term outcome following paracetamol exposure are needed to
inform all stakeholders on the full effect–side effect balance of the different strategies
to treat pain.
Keywords: acetaminophen, paracetamol, newborn, infant, procedural pain management, opioid sparing, pain
prevention, pain treatment
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INTRODUCTION
More than 30 years ago, the “credo” that immaturity protects
(pre)term infants from pain sensations and its side effects got
rejected by Anand et al. as he reported that untreated (i.e., surgery
without opioids) pain during surgery (using the patent ductus
arteriosus ligation in preterm neonates as a model) resulted in
both increased mortality and morbidity (like endocrine stress
response or post-operative infections). Moreover, these side
effects were not only restricted to the neonatal admission as it also
was more recently published that the impact of inadequate pain
handling was also observed in later infancy and beyond (1, 2).
Consequently, effective pain management in neonates matters.
This is not only related to ethical constraints or human empathy,
but evenmore because pain treatment is an important and crucial
part of contemporary medical, paramedical, and nursing care to
improve the outcome in neonatal intensive care graduates.
Inadequate management of pain in (pre)term neonates
changes or affects the thresholds of pain, pain or stress-related
behavior, and physiological responses and contributes to
impaired neurodevelopmental outcome. The maturational
development of the peripheral and central nervous system
is driven by a mix of processes and mechanisms, including
proliferation of cells, their subsequent migration and
differentiation, and also selective cell death, with apoptosis
as a related mechanism. These anatomic findings have their
functional correlates in the physiological balance between the
excitatory and the inhibitory interactions between cells. Because
the maturational changes throughout infancy are associated
with plasticity over time of these nociceptive systems, the
excitatory input as a consequence of the nociceptive input
may result in population-specific, lasting alterations in pain
processing patterns (3–6). Based on the very same concept
of a physiological dysbalance between the excitatory and the
inhibitory interactions between neurons, it is reasonable to
anticipate that (over)exposure to analgesics will likewise result
in (over)inhibition of these interactions, especially in a setting of
absence of excitatory-related pain. Although this is still mainly
based on animal experimental observations, this can also result
in poorer neurodevelopmental outcome in neonates (7).
In the human (pre)term newborn, there are arguments
that the limbic system displays a given vulnerability for
overexposure to pain, stress, or drugs, like analgesics or
sedatives. This is likely because the maturational changes in
the limbic structures evolve at a very fast rate throughout
the last trimester of pregnancy until late infancy. It is well-
known that the limbic system, with the hippocampus and
the regions connected to the hippocampus, is essential as a
functional switch board to encode, consolidate, and retrieve
memory. Intriguingly, these type of memory deficits are
frequently observed in former neonatal intensive care (NICU)
graduates (8). These long-term neurodevelopmental outcome
findings should be considered when decisions are made on the
balance between efficacy and safety. At best, this should be
combined with the published observations on the short-term side
effects of narcotics—mainly morphine—that were reported as
secondary outcome variables of the placebo-controlled trials on
pre-emptive morphine administration in preterm neonates that
undergo ventilation.
The reported short-term side effects associated to opioid
exposure in preterm neonates include hypoventilation and
apnea, low blood pressure, intestinal hypoperistalsis, and bladder
dysfunction. Hypoventilation and apnea resulted in prolonged
duration [7 (4–20) days in morphine-exposed group compared
to 6 (3–19) days in the placebo group, + 1 day of ventilation]
(9). Along the same line, Hartley et al. recently reported that
morphine (single oral, 100µg/kg dose) in non-ventilated preterm
infants, used to facilitate the screening for retinopathy of
prematurity (ROP) in the Procedural Pain in Premature Infants
(POPPI study) and to blunt the pain response, resulted in a high
incidence (8/15 vs. 3/15, relative risk 2.7, number needed to harm
= 3) of either newly occurring apneic events or an increase in
the number of such events in the morphine-exposed group (10).
Because of these safety-related findings (sufficient evidence of
harm), the POPPI study was terminated early (10). The available
data on the severity and the incidence of low blood pressure in the
different studies also likely reflect differences in morphine doses
and subsequent morphine exposure. In the NEOPAIN study,
the morphine maintenance (10–30 µg/kg/h) dose, the use of
additional morphine boluses, and the immaturity (reflected by
a younger age in cases) were associated with a higher risk to
observe low blood pressure as an adverse event (11). In contrast,
Simons et al. (morphine maintenance infusion, 10 µg/kg/h) did
not observe lower blood pressure in morphine-exposed preterm
neonates nor in inotropic prescription practices, irrespective
of the post-menstrual age, within their randomized, placebo-
controlled study (12). Finally, morphine delayed the attainment
of full enteral nutrition (secondary analysis) by 3 days [17 (12–26)
in the placebo arm compared to 20 (13–29) days in the morphine
arm] in the NEOPAIN trial (13).
Consequently, a balanced approach, considering both wanted
and unwanted effects, is appropriate, and data on drug utilization
of analgesics hereby provide us some insights in the epidemiology
and trends of drug prescription practices, and this also includes
paracetamol (14–17).
EPIDEMIOLOGY OF DRUG PRESCRIPTION
PRACTICES OF ANALGESICS IN
NEONATES
Research on prescription practices provide us with information
on trends over time, on between unit variability, or heterogeneity
in practices and on to what extent impact guideline development
and implementation changes these practices. At present, such
data are available for opioid use in neonates but are still
fragmented for paracetamol.
The Pediatrix group has a tradition to report on prescription
practices and its trends within their network. When we compare
two consecutive cohorts (1997–2004 vs. 2005–2010), fentanyl
and morphine were in the top 30 list (19/30 and 25/30,
prescriptions observed in 56/1,000 and 35/1,000 hospitalized
neonates, respectively) in the first cohort (1997–2004) to rise
to position 7 and 14 (exposure observed in 70 and 51/1,000
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admitted neonates) in the more recently (2005–2010) treated
cohort (14, 15). In another analysis of the same Pediatrix
database with focus on 8,591 preterm (<32 weeks gestational
age) ventilated neonates, opioid prescription rose from 5 to 32%
of the days on ventilation over the time interval. This increase
is observed despite the fact that there is a meta-analytical,
Cochrane level of evidence not to prescribe opioids systematically
in this setting, but rather “as needed” (17, 18). Besides the
increase, the Canadian network and the EUROPAIN cohort also
reported on the heterogeneity in prescription patterns between
different units. In the Canadian network, an extensive between-
unit variability in exposure (3 to 41% of admissions) to analgesics
was observed, and these differences were not explained by clinical
characteristics like surgery (19, 20). A similar pattern, including
regular (26%) opioid prescriptions and significant between-unit
variability in practices, was observed in the EUROPAIN study
(243 units, 6,680 neonates) (19, 20).
Finally, the implementation efforts resulting in the bedside
implementation of structured guidance on opioid prescription
are effective to lower the use and the variability between units
(21). This reduction in morphine prescription can be quantified
by the number of exposed neonates (33% instead of 63%,−47%)
or the cumulative morphine (0.51 mg/kg instead of 1.64 mg/kg,
−68%) dose in opioid-exposed neonates. To further stress the
clinical relevance of such implementation efforts, this exercise
also resulted in an important and statistically significant decrease
(from 10/205 to 3/250 cases) in neonates for whom methadone
was prescribed to treat iatrogenic neonatal abstinence syndrome
(21). Rana et al. have not described their data on paracetamol
prescriptions, but the paper supplement at least suggests that
these pain treatment guidelines resulted in more paracetamol
prescription, both when considering the cases exposed as well as
the duration of exposure in these cases (21).
As pain management in (pre)term neonates remains one of
the core businesses of contemporary neonatal care and because
of the side effects of opioids as mentioned earlier, there is
hereby also a shift in practices to avoid opioids toward non-
pharmacological interventions and paracetamol (22, 23). Data on
prescription practices provide us with information but are still
fragmented and anecdotic for paracetamol. The overall pattern
hereby suggests that paracetamol is somehow a “rising star”
in NICU pain management. This is reflected in the Pediatrix
database mentioned earlier and the NEOPAIN study. While
still absent in the top 30 in the first (1997–2004) cohort,
paracetamol appeared in position 16 (43/1,000 prescriptions)
in the more contemporary (2005–2010) cohort (15, 16). In the
EUROPAIN study, paracetamol prescription (14%) was more
common than that of sedatives/hypnotics (12%) but still lower
when compared to opioid exposure (26%). Besides the guideline-
driven decrease in morphine use as mentioned earlier and the
increased paracetamol prescription of Rana et al., there is another
recent paper on a clinical guideline-driven impact of reduced
exposure to morphine and increased use of paracetamol (21, 24).
Baarslag et al. reported that the adherence to a protocol that
subsequently implemented intravenous paracetamol as a first-
line treatment of pain after a major non-cardiac surgery in
neonates and infants resulted in low (add-on) morphine needs,
similar to the extent as published in the initial placebo-controlled
randomized trial on the effect of intravenous paracetamol on
post-operative morphine exposure (24, 25). In a recent report on
post-surgery analgesic and sedative drug use in a single NICU
(Lyon, France), paracetamol was routinely administered to 92%
of the admitted neonates as part of a multi-modal analgesia
approach (26).
Likely because of the uncertainties related to the pain
assessment tools during the registration studies, intravenous
paracetamol product registration for neonates failed in the
United States, while labeling in Europe is limited to term
neonates and beyond, not covering the needs of preterm
neonates. Despite this setting, there is an important off-label
prescription in (pre)term neonates (27, 28). In this review, we
aim to provide the reader with the currently available data on the
use of paracetamol as analgesic for the different pain syndromes
(major surgery, minor surgery or trauma, and procedural pain),
with focus on the limitations of paracetamol when prescribed for
neonatal procedural pain management. We will hereby explicitly
not discuss other indications (patent ductus arteriosus and fever).
To put these findings into perspective, this is preceded by an
overview on the pharmacology of paracetamol in this population
and will be followed by a reflection on some more recently
reported issues related to the safety of paracetamol with the
intention to describe the currently available risk/benefit profile
of this compound in the NICU setting.
THE CLINICAL PHARMACOLOGY OF
PARACETAMOL IN NEONATES
Pharmacology and Clinical Pharmacology
of Paracetamol
Paracetamol has pain- and fever-reducing effects, be it with
only very modest anti-inflammatory properties in the peripheral
tissues. Because of these modest peripheral properties, the
effect compartment is better reflected by the cerebrospinal fluid
compartment and not so much by the plasma compartment. The
routes of administration are variable since this can be done by
oral, rectal (enteral), or intravenous route.
Interestingly, after being marketed for almost 120 years,
the mechanisms of actions for paracetamol are still only in
part captured. There is concentration-dependent inhibition of
the prostaglandin H2 synthetase (PGHS) enzyme. This PGHS
complex has two sites: the cyclo-oxygenase (COX) site and the
peroxidase (POX) site (28–31). Paracetamol hereby interacts
with the POX enzyme as a reducing co-substrate so that less
prostaglandin G2 will be altered to prostaglandin H2 at the POX
site of this PGHS enzyme. Paracetamol-related POX co-substrate
inhibition is competitive since it is in balance with prostaglandin
G2 itself and by hydro-peroxides. This explains why the
inhibition of prostaglandin synthesis is potent within the central
nervous system (no lipid hydro-peroxides since the main sources
of these peroxides are leukocytes and platelets). Paracetamol
obviously has also the same competitive inhibition on peripheral
COXs. However, this inhibitory action in peripheral tissues
only occurs at physiological, normal low arachidonic acid
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concentrations as it is a competitive inhibition phenomenon.
This also explains the difference between paracetamol and
“real” non-steroidal anti-inflammatory drugs (NSAIDs) like
ibuprofen or indomethacin. As their interaction with the COX
enzyme is not competitive, NSAIDs has more potent anti-
inflammatory peripheral effects, even more in an inflammatory
(high hydro-peroxides and high prostaglandins) setting (30).
The other mechanisms relate to the formation of an active
metabolite (p-aminophenol) that interacts with cannabinoid
receptors. The other mechanisms of paracetamol’s pain-relieving
effects are further mediated by descending serotonergic pathways
activation, substance P-mediated processes, or interaction with
the N-methyl D-aspartate (NMDA) receptor or nitrous oxide-
related effects when acting as a spinal neurotransmitter (28–31).
In both adults and children, the paracetamol concentrations
of 5 and 10 mg/L have been postulated for either temperature
or pain relief (29). Although such target concentrations may
be different in (pre)term neonates because of maturational
differences, these targets are used to develop age-adapted and
route-tailored dosing regimens. In this target concentration
range, paracetamol is mainly metabolized by the liver into
paracetamol-glucuronide (47–62%) and paracetamol-sulfate
(25–36%) with subsequent renal excretion in adults and children.
Only 1–4% is excreted unaltered as paracetamol in urine, while
a minor route (8–10% of paracetamol) undergoes oxidation to
3-hydroxy-paracetamol to result in the toxic (liver and kidney)
metabolite N-acetyl-p-benzoquinone-imine (NAPQI). Age- or
weight-driven alterations in paracetamol pharmacokinetics and
metabolism have been observed throughout pediatric life but
are most relevant throughout infancy (first year of life). As
a consequence, not only total clearance but also the different
routes of elimination will change over age or weight. These
changes necessitate the integration of this knowledge on age- or
weight-specific paracetamol disposition data to targeted dosing
and subsequent exposure before we can consider studying age
category-specific pharmacodynamics (PD) (effects, but also for
side effects). Issues on short-term safety and tolerance on
paracetamol mainly relate to hepatotoxicity or hemodynamics,
while long-term safety relate to neuro-behavioral (attention
deficit hyperactivity disorder, autism spectrum disorders, and
intelligence) outcome, atopy, or fertility (7, 27). Both aspects will
be considered in the discussion part of the paper.
Clinical Pharmacology of Paracetamol in
Neonates
Clinical pharmacology wants to describe and predict the
(side)effects based on the pharmacokinetics (PK) and
pharmacodynamics for a given drug. PK (absorption,
distribution, metabolism, and excretion, ADME) describes
the concentration over time pattern (“what the body does to
the drug”) in a given compartment, like plasma, subcutaneous
tissue, or cerebrospinal fluid, for a given drug. PD describes the
relationship between drug concentrations and (side)effects over
time (“what the drug does to the body”) (32). For paracetamol,
this can be illustrated by concentration–time profiles in
plasma or cerebrospinal fluid for PK, while PD covers both
effects (analgesia and fever) and side effects (blood pressure,
hypothermia, and hepatic or renal impairment) (27, 33). Besides
the mean or average values, clinical pharmacology also aims to
describe the extent of variability and its covariates. This is where
neonatal clinical pharmacology has its specific characteristics
since differences between and within patients are the key
and core characteristics of neonatal clinical pharmacology
(34). This is also true for paracetamol PK and metabolism in
(pre)term neonates.
Besides very rare but specific clinical scenarios like peripartal
asphyxia and subsequent whole body hypothermia or the use
of cardiorespiratory support devices, data on paracetamol
pharmacokinetics and metabolism were reported throughout
neonatal age or weight ranges. As recently suggested,
physiologically based pharmacokinetic approaches should
hereby be considered to facilitate and guide the clinical studies
in these specific populations, incorporating both maturational
and non-maturational covariates of variability in paracetamol
disposition (35).
Based on the data on paracetamol pharmacokinetics and
metabolism mentioned earlier and when aiming for the same
target concentration as in adults or children (10 mg/L), we have
suggested to use a loading dose (20 mg/kg, once) approach,
to be followed by 10 mg/kg (q6h) of intravenous paracetamol
in late (pre)term neonates (36). Aiming for the same target
concentration, oral doses are similar (median estimates, not
reflecting the additional absorption-related variability), with
rectal administration of 25 to 30 mg/kg/day in preterm neonates
of 30 weeks gestation, 45 mg/kg/day in preterm infants of
34 weeks gestation, and 60 mg/kg/day in term neonates
suggested (all doses as suggested are off-label). Compared to the
intravenous route, the subsequent peak concentration after oral
dosing is observed about 1 h after administration. Absorption
after rectal administration is even more variable, blunted, and
delayed. The route-dependent impact can be explained by the
route-related difference in bio-availability, while the suggestion
to use a loading dose can be explained by the maturational
changes in distribution volume (higher in more immature
patients). Finally, the maturational changes in clearance are
reflected in the age-dependent differences in maintenance doses.
Absorption
Pharmacokinetic datasets after enteral (rectal and oral) or
intravenous administration were pooled to estimate the
absorption patterns. Intravenous administration hereby bypasses
the absorption-related variability associated with the oral or
the rectal route (36–38). The bioavailability following rectal
administration not only displayed age-dependent changes but
also depended on the formulation used as—relative to elixir—the
bioavailability of the solution was 0.66 (38). A decrease in
bioavailability with increasing age from 0.92 (22%) at 28 weeks
to 0.86 at 2 years was observed, whereas the triglyceride base
formulation bioavailability decreased from 0.86 (35%) at 28
weeks to 0.5 at 2 years. Studies have repeatedly documented
that the rectal route results in not only lower but also more
erratic absorption compared to the oral route. Consequently,
higher doses are needed when compared to oral administration,
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although it remains difficult to adapt dosing for the extent
between observation and between individual variability (39, 40).
As recently illustrated by Kleiber et al., the bioavailability after
oral administration also displays variability (72, 11–91%) in
young infants during intensive care admission (41).
Distribution
The relative distribution volume (L/kg) has a progressive
decrease over time from 27 weeks post-menstrual age onwards
to reach an adult-equivalent value for 6 months of age onwards
(42, 43). As a consequence, the effect of a loading dose is over
even more clinical relevance in early neonatal life. As their
relative distribution volume (L/kg) for paracetamol is higher, the
same mg/kg dose will result in a lower peak concentration in
the setting of a higher distribution volume, while a lower peak
concentration is likely associated with poorer pain control (43).
Metabolism and Elimination
Pharmacokinetic datasets were pooled to report on clearance
and metabolism following either enteral (rectal and oral) or
intravenous administration (36, 37, 42). Patient size (reflected
in weight) is the dominant covariate to explain in-between
variability in paracetamol clearance in early life. Using these
pooled datasets, amean target paracetamol of 11mg/L in serum is
anticipated in neonates (between 32 and 44 weeks post-menstrual
age) when exposed to (maintenance doses and loading, cf.
higher) intravenous paracetamol of 10 mg/kg (q6h) (36). Besides
estimates on overall clearance, data on the different metabolic
elimination routes (glucuronidation, sulfation, oxidation, and
renal) were described and even prospectively confirmed (44–
46). More recently, Flint et al. reported on the gestational
age-determined raise in glucuronidation capacity in extreme
preterm neonates. Importantly, this was without any evidence for
saturation of a specific pathway like oxidation or sulfation (47).
PARACETAMOL AS ANALGESIC IN
NEONATES: A SUMMARY OF THE
AVAILABLE EVIDENCE
A structured literature search was conducted in PubMed
(November 2019, paracetamol + pain + newborn, preterm, or
infant as keywords). This search resulted in 205, 33, and 468 hits,
respectively. Following title, abstract, and full paper reading when
perceived to be relevant to this review (this includes verification
of references and a search for resulting citations), a summary
of the available observations on the relevance of paracetamol as
analgesic in neonates was constructed.
Paracetamol and Opioid-Sparing Effects in
Major Pain Syndromes in Neonates
There is meta-analytical evidence on the opioid-sparing effects
of paracetamol administration to treat post-operative or post-
traumatic pain in adults and in children. In contrast, the
demonstration of a clinically significant reduction in opioid-
related adverse effects (like sedation and nausea) is much
less robust (48, 49). In contrast, data in neonatal cohorts
on paracetamol-related opioid-sparing effects in neonates were
only more recently reported in two different cohorts (surgical
and medical intensive care, respectively). After a major non-
cardiac surgery in (pre)term neonates, Ceelie et al. documented
a clinically significant (−66%) morphine (maintenance dose)
sparing effect in neonates and in infants co-exposed to
intravenous paracetamol (25). In contrast, rectal paracetamol had
no effect on morphine use after a major non-cardiac surgery
in young infants, likely because of the variability in absorption
and the doses used (90–100 mg/kg/day) (50). This assumption
is further supported by a pilot study conducted in the same unit
comparing intravenous (n = 12) vs. rectal (n = 14) paracetamol
(both at 40 mg/kg/day) in young infants following a major
craniofacial surgery. Intravenous paracetamol use proved to
be more effective than rectal paracetamol using COMFORT-B
scores (above 17, 9/14 vs. 3/14) as outcome variable of interest
(51) (Table 1) (25, 50, 52). As discussed earlier, Baarslag et al.
reported that protocol adherence to implement intravenous
paracetamol as a first-line treatment of pain after a major non-
cardiac surgery in neonates and infants resulted in low (add-
on) morphine needs, similar to the extent as published in this
placebo-controlled randomized trial.
Along the same line but in amedical NICU setting, a reduction
in opioid administration (−54% for cumulative dose and −59%
for number of additional boluses) to extreme preterm neonates
(<32 weeks) was documented following the systematic use of
intravenous paracetamol as a first-line analgesic in a clinical pain
management protocol of a single NICU (Oulu, Finland) (52).
Paracetamol and Minor to Moderate Pain
Syndromes in Neonates
Data on the impact of paracetamol to take care of minor
to moderate pain syndromes in (pre)term neonates were
quantified and reported following a “minor” surgery (one study,
circumcision of 44 neonates) or following a birth-associated
tissue damage [assisted vaginal delivery, bruising, three studies,
264 (pre)term neonates] in a randomized, placebo-controlled
setting. In addition, there is also a retrospective analysis
on the impact of intravenous paracetamol (prophylactic, for
patent ductus arteriosus closure) on glucose 33% consumption
and additional analgesics prescribed compared to a historical
cohort (449 neonates) in a single (Innsbruck, Austria) NICU
(Table 2) (53–57).
Paracetamol (15mg/kg, every 6 h for 24 h, oral) was ineffective
as analgesic at and immediately after circumcision. However,
there was some advantage (as the post-operative comfort
score was lower compared to that of the controls) for the
paracetamol-exposed cases afterwards (>6–24 h after the surgical
intervention) (55). In a randomized, placebo-controlled study
following assisted delivery (vacuum extraction and pre-emptive)
in 122 term neonates, paracetamol (20 mg/kg, rectal, once)
improved the initial clinical gestalt (e.g., drinking behavior), be
it without any differences in the quantification of the pain as
observed. Subsequent paracetamol dosing did not result in any
difference in outcome, but neither was there any difference in side
effect (53). In a very analog study in 123 (near)term neonates (20–
25 mg/kg rectal route, 2 and 8 h post-natal age, pre-emptive), the
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TABLE 1 | Studies on the relevance of paracetamol on pain (opioid reduction) during major pain syndromes in neonates (25, 50, 52).
Reference Study design, pain model Paracetamol dosing Results
Van der Marel et al.
(50)
Double-blind RCT, morphine + paracetamol or
placebo, 30/54 PMA <45 weeks. Visual analog
Scale (VAS) and comfort score.
Major thoracic (lung, esophageal) or
abdominal surgery
Rectal paracetamol
30–40 mg/kg loading dose, 20–30
mg/kg, q6h or q8h,
maintenance dose
Cases < PMA 45 weeks needed less add on
morphine compared to infants, but without
any difference between both study arms
(paracetamol or placebo) (threshold for
additional morphine, ≥VAS)
Ceelie et al. (25) Double-blind RCT, 71 neonates and infants
(35/71 <10 days post-natal). Major thoracic
(lung, esophageal) or abdominal surgery. Nurse
rating scale-11 + comfort-B, cumulative
maintenance dose of morphine was assessed
Morphine loading dose, followed by
either continuous morphine or
paracetamol i.v. (48 h). Backup
morphine
No differences in pain scores Clinical relevant
lower (−66%) exposure to morphine for the
continuous morphine when compared to the
paracetamol group
Härmä et al. (52) Retrospective, “unblended” analysis (two
consecutive time intervals) on opioid
prescription in 218 preterm neonates (<32
weeks) before or following the use of
intravenous paracetamol in the clinical pain
management protocol (Neonatal Infant Acute
Pain Assessment Scale) of a single Finnish unit
20 mg/kg intravenous as loading
dose, followed by 7.5 mg/kg, q6h
(maintenance)
Paracetamol-exposed neonates needed
significantly fewer morphine doses, 1.78
[(4.56) vs. 4.35 (11.53)] and had a lower total
morphine exposure [0.17 (0.45) vs. 0.37
(0.96) mg/kg]. No differences in pain score,
days on ventilation of incidence of apneas
RCT, randomized, controlled trial; PMA, post-menstrual age; LNPS, Leuven Neonatal Pain Scale; VAS, Visual Analog Scale.
TABLE 2 | Studies on the relevance of paracetamol on pain during minor to moderate pain syndromes in neonates (53–57).
Reference Study design, pain model Paracetamol dosing Results
Van Lingen et al. (53) RCT, 122 term neonates following
instrumental vaginal delivery
Facies pain scale + “gestalt” assessment
Rectal (20 mg/kg, q6h) for 24 h, either
paracetamol or placebo after delivery
Similar Facies pain scores, objective clinical
symptoms (nurse assessment) similar, except
for the paracetamol group 1 h after first
administration (better “gestalt” assessment)
Tinner et al. (54) RCT, EDIN (Echelle de douleur et d’inconfort
du nouveau né) score in the 24 h following
instrumental vaginal delivery in 123 (near)
term neonates.
BPSN (Bernese pain score) following heel
lancing on day 2–3 in the same neonates,
with 0.2ml sucrose in all cases.
Rectal paracetamol (20–25 mg/kg) 2
and 8 h after delivery
No differences in mean EDIN score, no
differences in EDIN score ≥5.
BPSN after heel prick higher in the “former”
paracetamol group [5 (3–9) vs. 3 (0–6)]
Howard et al. (55) RCT in 44 healthy term neonates that
underwent neonatal circumcision (Gomco).
Post-operative comfort score
Oral paracetamol
15 mg/kg, q6h for 24 h
start 2 h before surgery
No effects during and immediately following
circumcision.
Post-operative score similar until 6 h, but
paracetamol group scored better
afterwards (>6 h).
Allegaert et al. (56) Open-label intravenous paracetamol (19/60
mono-therapy). Instrumental vaginal delivery
or bruising with Leuven Neonatal Pain Score
(LNPS) indicating pain
Loading dose intravenous
Paracetamol (20 mg/kg)
Decrease in LNPS from 0.5 h onwards, with a
trend to return to these baseline scores at 5 h
Höck et al. (57) Retrospective study design. Prophylactic
paracetamol use in preterm (≤32 weeks, n =
221 vs. 228), in the first days of life,
prophylactic to induce patent ductus
arteriosus closure vs. historical data. Clinical
pain assessment based on BNPS
Intravenous paracetamol (10 mg/kg,
q8h)
Less 33% glucose use (protocol = to treat
mild to moderate pain, mean 13.48 vs. 8.71
doses) in exposed cases, but no impact on
the prescription of systemic analgesics
RCT, randomized controlled trial; EDIN, Echélle de douleur en d’inconfort du nouveau-né; BPSN, Bernese pain score.
pain scores remained low irrespective of paracetamol exposure
following assisted vaginal delivery. However, the neonates that
were initially exposed to paracetamol at delivery had a more
vigorous and pronounced response (Bernese pain score) during
heel lancing on post-natal days 2 and 3 (54). As mentioned, both
studies used a pre-emptive prescription approach, so the initiated
treatment was irrespective of the presence of pain at initiation. In
contrast, an open-label study in neonates (n = 19) with pain (as
assessed by a pain score) following a birth-related tissue damage
resulted in lower pain scores within 0.5 h after the administration
of intravenous paracetamol (20 mg/kg, loading dose), with a
slight return toward these higher baseline scores after 5 h (56).
In our assessment, the available body of evidence suggest
that paracetamol is likely effective in the presence of minor to
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moderate pain, but not when prescribed as part of a pre-emptive
strategy. However, using a retrospective analysis, prophylactic
“low”-dose paracetamol (10 mg/kg, q8h) administration in
preterm (≤32 weeks) neonates with the intention to induce the
closure of the patent ductus arteriosus was associated with a
reduced prescription of 33% glucose (protocol = to treat mild
to moderate pain) in exposed (mean 13.48 vs. 8.71 doses) cases,
but without significant differences in the prescription of systemic
analgesics (57).
Paracetamol for Acute Procedural
Analgesia in Neonates
It is important to realize that the available information strongly
suggests that paracetamol fails to reduce acute procedural [skin-
breaking procedures like heel lancing or peripherally inserted
central catheter (PICC) placement and ROP screening] pain (58,
59). To further illustrate this, we have summarized the available
information on heel lancing (60–63) and ROP (64–66) screening
(Tables 3, 4).
Table 3 (60–63) gives a condensed summary of the retrieved
randomized studies (cf. search strategy described earlier) on
paracetamol administration for procedural-related pain relief
during heel lancing (352 cases, four studies). There was
no benefit (improved pain control) in cases exposed to
paracetamol when compared to placebo. When compared
to non-pharmacological interventions (sucrose and dextrose),
paracetamol-related analgesia was less effective to these non-
pharmacological interventions. Similarly, Roofthooft et al. also
concluded that intravenous paracetamol (10, 15, or 20 mg/kg)
was not effective (PIPP score and Comfort-Neo) as an analgesic
during PICC placement in 60 preterm (<32 weeks) neonates,
irrespective of the dose administered (67). This is in line with
similar findings on the absence of an analgesic effect of even
high doses of paracetamol (40 mg/kg oral) on pain, fear, or
distress as reported in a cohort of children with oncological
diseases when they had to undergo a needle insertion into
their subcutaneous implanted venous access (68). This suggests
that, when considering the pain syndromes and the efficacy of
paracetamol, neonates do not behave differently from children.
Table 4 illustrates the same limitations of paracetamol when
assessed for its analgesic properties during an eye examination
to screen for ROP (252 cases, three studies) in (pre)term
neonates. Only one of these studies described a very modest
decrease in median PIPP value (12 vs. 14), but not within the
range usually aimed for to qualify an intervention as effective
(64). Sucrose was effective compared to either paracetamol or
placebo (65), and oral morphine (200 µg/kg) tended to result
in lower pain scores. However, as mentioned earlier, in the
POPPI study, oral morphine (100 µg/kg) was associated with
either a higher incidence of newly occurring apneic events or
an increase in the number of such events in the morphine-
exposed group. Because of these safety-related findings (sufficient
evidence of harm), the POPPI study was terminated early
(10). Based on the currently available evidence, it seems
that a non-pharmacological intervention, based on a bundled
developmental care intervention concept, resulted in a clinically
relevant reduction in the pain and stress responses and in
the time needed to recover (69). It is therefore suggested that
“combined” practices are likely the approach needed to make
further progress or should at least be the background setting to
assess the impact of additional interventions.
Paracetamol fails to reduce acute procedural pain in neonates
(58, 59), but this should be put in some perspective. The
observation on, e.g., circumcision instructs us that paracetamol
does not improve pain scores in the first 6 h after the intervention,
but the paracetamol group scored better afterwards (>6 h) (55).
A similar pattern has been described for paracetamol use during
and after immunization in infants. There is a significant benefit
from paracetamol prophylaxis for fever and fussiness in the first
24 h after immunization, but not yet for analgesia during the
needle-related procedure (70).
PARACETAMOL USE IN NEONATES: IN
SEARCH OF A BETTER BENEFIT–RISK
BALANCE
Pain management in (pre)term neonates remains one of the core
businesses of contemporary neonatal care. Because of the early
and delayed negative effects of opioids, there is amore recent shift
in practices to avoid opioids and gear toward paracetamol or non-
pharmacological interventions (22, 23). Related to this shift in
practices, the available observations on paracetamol disposition
and the dynamics of paracetamol in (pre)term neonates have
“exploded” over the last two decades. We therefore summarized
the evidence on the impact of paracetamol to treat major
pain syndromes (effective to reduce opioid consumption) in
minor to moderate pain syndromes (effective as monotherapy)
or in procedural pain management (fails) in neonates. In
search of a better benefit–risk balance, these findings should be
further considered.
Firstly, the practice to administer paracetamol in settings
where the available data strongly suggest that such practices
are not effective should not result in established “common”
practice (efficacy) and acceptance of a substandard setting but
should stimulate us to further search for more effective and
safer interventions. Secondly, avoidance or reduction of opioid
exposure is a valid target, but it is perhaps too simple to assume
that paracetamol is a benign drug without any side effects as it has
effects on cytokine production that are only partly understood
(safety) in the developmental context of the (pre)term neonate.
Some epidemiological data and experimental studies in juvenile
animals call for additional safety assessment studies.
Related to the needed search for more effective and
safer interventions, this should, for sure, also include non-
pharmacological interventions, like a care bundle to blunt the
pain response during ROP screening (69). Even more relevant
are technical adaptations in our practices and interventions that
can be very effective to avoid or reduce pain. A venipuncture
is more effective, is faster, and is associated with a less robust
pain response compared to heel lancing (71); the use of a
lens instead of an eye lid distractor results in a reduced pain
response during ROP screening (72), while an assisted delivery
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TABLE 3 | Studies on the relevance of paracetamol on pain during heel lancing in neonates (60–63).
Reference Study design, heel lancing Paracetamol dosing Results
Shah et al. (60) RCT, 75 full-term cases.
Facial action pain scores and
cry score.
Oral paracetamol, 20 mg/kg or
placebo, once 1–1.5 h before prick
Similar facial action pain scores between
both groups. Neither any difference in cry
score
Bonetto et al. (61) RCT, 76 full-term cases.
Pain scores (NIPS, neonatal infant
pain score >4)
Placebo, glucose (25%)
EMLA or oral paracetamol (20
mg/kg, 60min)
NIPS < 4 similar between placebo,
paracetamol, or EMLA (47, 42, and 63%).
Oral dextrose most effective (84% NIPS <
4, NNT 2.7)
Badiee et al. (62) RCT, 72 preterm (mean 32 weeks)
cases.
PIPP (premature infant pain
profile) score
High dose, oral paracetamol (40
mg/kg), once 1.5 h 90 before heel
lancing
PIPP scores placebo were similar between
placebo and paracetamol (9.7, SD 4.2 vs.
11.1, SD 3.8)
Foronda et al. (63) Randomized, single-blinded study
in 129 cases, NIPS, and PIPP
score, paracetamol (42) to glucose
(47) or placebo (40)
No data on the paracetamol dose
provided
PIPP and NIPS score were lower, and
crying time shorter in the glucose group
No effect of paracetamol
RCT, randomized controlled trial; ELMA, eutectic mixture of local anesthetics; NNT, number needed to treat; SD, standard deviation; NIPS, neonatal infant pain score; PIPP, premature
infant pain profile.
TABLE 4 | Studies on the relevance of paracetamol on pain during retinopathy of prematurity (ROP) screening in neonates (64–66).
Reference Study design, ROP screening Paracetamol dosing Results
Kabatas et al. (64) RCT in 114 preterm neonates,
screening retinopathy of
prematurity. PIPP (premature infant
pain profile) score
Topical anesthetics + paracetamol
(15 mg/kg, oral, 60min) or placebo
Significant lower PIPP in paracetamol
exposed cases [12 (9–13) vs. 14
(13–15)], but very modest effect (cutoff
PIPP score <7)
Seifi et al. (65) RCT in 120 preterm neonates,
screening retinopathy of
prematurity. PIPP score
Sucrose 25% vs. oral paracetamol
(15 mg/kg) vs. placebo
Sucrose was effective, paracetamol not
when compared to placebo at eye
examination
Manjunatha et al. (66) RCT, examination retinopathy
of prematurity 18 preterms recruited
(63 intended), PIPP
Oral morphine (200 µg/kg) or
paracetamol (20 mg/kg) or placebo
Morphine cases tended to have lower
pain scores (PIPP), but no significant
differences (underpowered study)
with Kiwi OmniCup vs. metal ventouse is associated with a
decreased neonatal pain response irrespective of the use of
paracetamol (73).
Observations on short-term safety in (pre)term neonates
related to hepatic injury (74), hemodynamic tolerance (75),
and temperature regulation (76) have been reported (27, 74–
76). Similar to other populations, N-acetyl-cysteine serves as a
glutathione precursor to treat hepatotoxicity by reducing NAPQI
production, and experience on its use in neonates has been
summarized (27).
Long-term safety concerns relate to neuro-behavioral
(attention deficit hyperactivity disorder, autism spectrum
disorders, and intelligence) outcome, atopy, or fertility
and are mainly based on epidemiological data analysis
following maternal intake and subsequent fetal exposure.
The neuro-behavioral epidemiological data are supported
by postulated mechanisms and experimental observations
in animals. Suggested mechanisms relate to modulation
of central nervous system inflammation or to paracetamol
metabolites, like cannabinoids. Related to this, paracetamol
and 1(9)-tetrahydrocannabinol, but not ibuprofen, resulted
in developmental neurotoxicity in a mice model (77, 78).
Paracetamol exposure also results in reduced COX-2 activity in
the brain, as this is the crucial pharmacological effect for at least
fever reduction and likely also for analgesia. These differences
in phenotypic cerebral COX-2 activity are not only driven by
drug exposure (paracetamol, ibuprofen, and indomethacin) but
are also determined by genetic polymorphisms. Interestingly,
the cognitive outcome in former preterm neonates is in
part determined by COX-2 polymorphisms, with a lower
polymorphism-determined phenotypic activity resulting in
poorer outcome (79). The claimed mechanism related to atopy
is COX-dependent, the inhibition of mucosal PGE2 synthesis,
resulting in alteration of the maturational immunity (30).
Finally, an association between maternal paracetamol intake
and cryptorchidism or hypospadias has been described, with
endocrine disturbances as the mechanism (80).
Both the Food and Drug Administration and the European
Medicine Agency assessed the reported datasets in 2015 and in
2019, respectively, and concluded that the clinical translation
of these potential associations remains uncertain. This leads
to the decision not to adapt their guidance, while the leaflets
(summary of product characteristics, SmPC) were changed in the
specific section on fertility, lactation, and pregnancy (verbatim
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copied from SmPC, adapted wording is underlined and in italics:
“A large amount of data on pregnant women indicate neither
malformative, nor feto/neonatal toxicity. Epidemiological studies
on neurodevelopment in children exposed to paracetamol in utero
show inconclusive results. If clinically needed, paracetamol can be
used during pregnancy however it should be used at the lowest
effective dose for the shortest possible time and at the lowest
possible frequency”). Taking these uncertainties into account,
it is appropriate to include long-term outcome data into the
already existing and ongoing studies and cohorts to generate
data and create certainties on the existence and the extent of
any potential negative effects. This can be done by integrating
“pharmacovigilance” studies into long-term outcome studies, like
renal outcome following neonatal ibuprofen exposure (81). The
recent paper of Juurjärvi et al. on the post-discharge outcome (2
years) in a cohort of preterm neonates included in a prospective
study on prophylactic paracetamol prescription to induce ductus
arteriosus closure hereby serves as a relevant illustration that such
data can be generated (82–84).
In conclusion, effective and safe painmanagement in neonates
matters. This is not only related to ethical constraints or human
empathy but even more because pain treatment is an important
and crucial part of contemporary medical, paramedical, and
nursing care to improve the outcome in neonatal intensive care
graduates. Based on the available evidence, paracetamol has
opioid-sparing effects for major pain syndromes, is effective to
treat minor to moderate pain syndromes, but fails for procedural
pain management in neonates. However, there are also upcoming
association type of epidemiological studies on the relation
between exposure to analgesics—including paracetamol—and
the negative short- or long-term outcome characteristics (neuro-
behavioral, atopy, and fertility). Because of these dual findings,
further research is needed. This includes a search for other
effective strategies to prevent or treat pain. This includes
the collection of data on long-term outcome and also after
paracetamol exposure to inform all relevant stakeholders on the
efficacy/safety balance.
AUTHOR CONTRIBUTIONS
KA developed the concept, performed and interpreted the
structured searches, and wrote and approved the paper.
REFERENCES
1. Anand KJ, Sippell WG, Aynsley-Green A. Pain, anaesthesia, and babies.
Lancet. (1987) 2:1210. doi: 10.1016/S0140-6736(87)91347-X
2. Anand KJ, Hickey PR. Pain and its effects in the human neonate and fetus. N
Engl J Med. (1987) 317:1321–9. doi: 10.1056/NEJM198711193172105
3. Hall RW, Anand KJ. Pain management in newborns. Clin Perinatol. (2014)
41:895–924. doi: 10.1016/j.clp.2014.08.010
4. Walker SM, Franck LS, Fitzgerald M, Myles J, Stocks J, Marlow N. Long-
term impact of neonatal intensive care and surgery on somatosensory
perception in children born extremely preterm. Pain. (2009) 141:79–87.
doi: 10.1016/j.pain.2008.10.012
5. Morton NS. The pain-free ward: myth or reality. Paediatr Anaesth. (2012)
22:527–9. doi: 10.1111/j.1460-9592.2012.03881.x
6. Johnston CC, Fernandes AM, Campbell-Yeo M. Pain in neonates is different.
Pain. (2011) 152:S65–73. doi: 10.1016/j.pain.2010.10.008
7. van den Hoogen NJ, de Kort AR, Allegaert KM, Joosten EA, Simons SHP,
Tibboel D, et al. Developmental neurobiology as a guide for pharmacological
management of pain in neonates. Semin Fetal Neonatal Med. (2019)
24:101012. doi: 10.1016/j.siny.2019.05.004
8. Schiller RM, Allegaert K, Hunfeld M, van den Bosch GE, van den Anker J,
Tibboel D. Analgesics and sedatives in critically ill newborns and infants: the
impact of long-term neurodevelopment. J Clin Pharmacol. (2018) 58(Suppl.
10):S140–50. doi: 10.1002/jcph.1139
9. Bhandari V, Bergqvist LL, Kronsberg SS, Barton BA, Anand KJ, NEOPAIN
Trial Investigators Group. Morphine administration and short-term
pulmonary outcomes among ventilated preterm infants. Pediatrics. (2005)
116:352–9. doi: 10.1542/peds.2004-2123
10. Hartley C, Moultrie F, Hoskin A, Green G, Monk V, Bell JL, et al. Analgesic
efficacy and safety of morphine in the procedural pain in premature infants
(Poppi) study: randomised placebo-controlled trial. Lancet. (2018) 392:2595–
605. doi: 10.1016/S0140-6736(18)31813-0
11. Anand KJ, Anderson BJ, Holford NH, Hall RW, Young T, Shephard B, et al.
Morphine pharmacokinetics and pharmacodynamics in preterm and term
neonates: secondary results from the NEOPAIN trial. Br J Anaesth. (2008)
101:680–9. doi: 10.1093/bja/aen248
12. Simons SH, Roofthooft DW, van Dijk M, van Lingen RA, Duivenvoorden
HJ, van den Anker JN, et al. Morphine in ventilated neonates: its effects on
arterial blood pressure. Arch Dis Child Fetal Neonatal Ed. (2006) 91:F46–51.
doi: 10.1136/adc.2004.069831
13. Menon G, Boyle EM, Bergqvist LL, McIntosh N, Barton BA, Anand
KJ. Morphine analgesia and gastrointestinal morbidity in preterm infants:
secondary results from the NEOPAIN trial. Arch Dis Child Fetal Neonatal Ed.
(2008) 93:F362–7. doi: 10.1136/adc.2007.119297
14. Allegaert K, Simons S, Van Den Anker J. Research on medication use in the
neonatal intensive care unit. Expert Rev Clin Pharmacol. (2019) 12:343–53.
doi: 10.1080/17512433.2019.1580569
15. Clark RH, Bloom BT, Spitzer AR, Gerstmann DR. Reported medication use in
the neonatal intensive care unit: data from a large national data set. Pediatrics.
(2006) 117:1979–87. doi: 10.1542/peds.2005-1707
16. Hsieh EM, Hornik CP, Clark RH, Laughon MM, Benjamin DK Jr, Smith PB,
et al. Medication use in the neonatal intensive care unit. Am J Perinatol. (2014)
31:811–21. doi: 10.1055/s-0033-1361933
17. Zimmerman KO, Smith PB, Benjamin DK, Laughon M, Clark R,
Traube C, et al. Sedation, analgesia, and paralysis during mechanical
ventilation of premature infants. J. Pediatr. (2017) 180:99–104.e1.
doi: 10.1016/j.jpeds.2016.07.001
18. Bellù R, de Waal K, Zanini R. Opioids for neonates receiving mechanical
ventilation: a systematic review and meta-analysis. Arch Dis Child
Fetal Neonatal Ed. (2010) 95:F241–51. doi: 10.1136/adc.2008.15
0318
19. Carbajal R, Eriksson M, Courtois E, Boyle E, Avila-Alvarez A, Andersen
RD, et al. Sedation and analgesia practices in neonatal intensive care units
(EUROPAIN): results from a prospective cohort study. Lancet Respir Med.
(2015) 3:796–812. doi: 10.1016/S2213-2600(15)00331-8
20. Borenstein-Levin L, Synnes A, Grunau RE, Miller SP, Yoon EW, Shah PS, et al.
Narcotics and sedative use in preterm neonates. J Pediatr. (2017) 180:92–8.
doi: 10.1016/j.jpeds.2016.08.031
21. Rana D, Bellflower B, Sahni J, Kaplan AJ, Owens NT, Arrindell EL
Jr, et al. Reduced narcotic and sedative utilization in a NICU after
implementation of pain management guidelines. J Perinatol. (2017) 37:1038–
42. doi: 10.1038/jp.2017.88
22. Mehler K, Oberthuer A, Haertel C, Herting E, Roth B, Goepel W, et al. Use
of analgesic and sedative drugs in VLBW infants in German NICUs from
2003-2010. Eur J Pediatr. (2013) 172:1633–9. doi: 10.1007/s00431-013-2095-3
23. van den Anker JN, Allegaert K. Treating pain in preterm infants:
moving from opioids to acetaminophen. J Pediatr. (2016) 168:13–5.
doi: 10.1016/j.jpeds.2015.09.061
24. Baarslag MA, Ista E, de Leeuw T, van Rosmalen J, Tibboel D, van Dijk M, et al.
Clinically effective implementation of intravenous paracetamol as primary
Frontiers in Pediatrics | www.frontiersin.org 9 March 2020 | Volume 8 | Article 89
Allegaert Paracetamol for Neonatal Procedural Pain Management
analgesia after major surgery in neonates and young infants. Arch Dis Child.
(2018) 103:1168–9. doi: 10.1136/archdischild-2018-315379
25. Ceelie I, de Wildt SN, van Dijk M, van den Berg MM, van den
Bosch GE, Duivenvoorden HJ, et al. Effect of intravenous paracetamol on
postoperative morphine requirements in neonates and infants undergoing
major noncardiac surgery: a randomized controlled trial. JAMA. (2013)
309:149–54. doi: 10.1001/jama.2012.148050
26. Benahmed-Canat A, Plaisant F, Riche B, Rabilloud M, Canat G, Paret N, et al.
Postsurgery analgesic and sedative drug use in a French neonatal intensive
care unit: a single-center retrospective cohort study. Arch Pediatr. (2019)
26:145–50. doi: 10.1016/j.arcped.2019.02.011
27. Pacifici GM, Allegaert K. Clinical pharmacology of paracetamol
in neonates: a review. Curr Ther Res Clin Exp. (2014) 77:24–30.
doi: 10.1016/j.curtheres.2014.12.001
28. van den Anker JN, Allegaert K. Acetaminophen in the neonatal intensive
care unit: shotgun approach or silver bullet. J Pediatr. (2018) 198:10–1.
doi: 10.1016/j.jpeds.2018.02.046
29. Anderson BJ. Paracetamol (Acetaminophen): mechanisms of action. Paediatr
Anaesth. (2009) 18:915–21. doi: 10.1111/j.1460-9592.2008.02764.x
30. Langhendries JP, Allegaert K, Van Den Anker JN, Veyckemans F, Smets F.
Possible effects of repeated exposure to ibuprofen and acetaminophen on the
intestinal immune response in young infants. MedHypotheses. (2016) 87:90–6.
doi: 10.1016/j.mehy.2015.11.012
31. Gibb IA, Anderson BJ. Paracetamol (acetaminophen) pharmacodynamics:
interpreting the plasma concentration. Arch Dis Child. (2008) 93:241–7.
doi: 10.1136/adc.2007.126896
32. van den Anker J, Reed MD, Allegaert K, Kearns GL. Developmental changes
in pharmacokinetics and pharmacodynamics. J Clin Pharmacol. (2018)
58(Suppl. 10):S10–25. doi: 10.1002/jcph.1284
33. Allegaert K, van den Anker JN. Perinatal and neonatal use of
paracetamol for pain relief. Semin Fetal Neonatal Med. (2017) 22:308–13.
doi: 10.1016/j.siny.2017.07.006
34. Allegaert K, van de Velde M, van den Anker J. Neonatal clinical
pharmacology. Paediatr Anaesth. (2014) 24:30–8. doi: 10.1111/pan.12176
35. Raffaeli G, Pokorna P, Allegaert K, Mosca F, Cavallaro G, Wildschut ED,
et al. Drug disposition and pharmacotherapy in neonatal ECMO: from
fragmented data to integrated knowledge. Front Pediatr. (2019) 7:360.
doi: 10.3389/fped.2019.00360
36. Allegaert K, Palmer GM, Anderson BJ. The pharmacokinetics of intravenous
paracetamol in neonates: size matters most. Arch Dis Child. (2011) 96:575–80.
doi: 10.1136/adc.2010.204552
37. Cook SF, Roberts JK, Samiee-Zafarghandy S, Stockmann C, King
AD, Deutsch N, et al. Population pharmacokinetics of intravenous
paracetamol (acetaminophen) in preterm and term neonates: model
development and external evaluation. Clin Pharmacokinet. (2016) 55:107–19.
doi: 10.1007/s40262-015-0301-3
38. Anderson BJ, van Lingen RA, Hansen TG, Lin YC, Holford NH.
Acetaminophen developmental pharmacokinetics in premature neonates and
infants: a pooled population analysis. Anesthesiology. (2002) 96:1336–45.
doi: 10.1097/00000542-200206000-00012
39. van Lingen RA, Deinum HT, Quak CM, Okken A, Tibboel D. Multiple-dose
pharmacokinetics of rectally administered acetaminophen in term infants.
Clin Pharmacol Ther. (1999) 66:509–15. doi: 10.1016/S0009-9236(99)70014-7
40. Hansen TG, O’Brien K, Morton NS, Rasmussen SN. Plasma paracetamol
concentrations and pharmacokinetics following rectal administration in
neonates and young infants. Acta Anaesthesiol Scand. (1999) 43:855–9.
doi: 10.1034/j.1399-6576.1999.430813.x
41. Kleiber N, Calvier E, Mooij MG, Krekels EHJ, Vaes WHJ, Tibboel D,
et al. Enteral acetaminophen bioavailability in pediatric intensive care
patients determined with an oral microtracer and pharmacokinetic
modeling to optimize dosing. Crit Care Med. (2019) 47:e975–83.
doi: 10.1097/CCM.0000000000004032
42. Anderson BJ, Pons G, Autret-Leca E, Allegaert K, Boccard E.
Pediatric intravenous paracetamol (propacetamol) pharmacokinetics:
a population analysis. Paediatr Anaesth. (2005) 15:282–92.
doi: 10.1111/j.1460-9592.2005.01455.x
43. Mian P, Knibbe CAJ, Calvier EAM, Tibboel D, Allegaert K. Intravenous
paracetamol dosing guidelines for pain management in (pre)term neonates
using the paediatric study decision tree. Curr Pharm Des. (2017) 23:5839–49.
doi: 10.2174/1381612823666170921143104
44. Krekels EH, van Ham S, Allegaert K, de Hoon J, Tibboel D, Danhof M,
et al. Developmental changes rather than repeated administration drive
paracetamol glucuronidation in neonates and infants. Eur J Clin Pharmacol.
(2015) 71:1075–82. doi: 10.1007/s00228-015-1887-y
45. Cook SF, Stockmann C, Samiee-Zafarghandy S, King AD, Deutsch N,
Williams EF, et al. Neonatal maturation of paracetamol (acetaminophen)
glucuronidation, sulfation, and oxidation based on a parent-metabolite
population pharmacokinetic model. Clin Pharmacokinet. (2016) 55:1395–411.
doi: 10.1007/s40262-016-0408-1
46. Hammer GB, Maxwell LG, Taicher BM, Visoiu M, Cooper DS, Szmuk P, et al.
Randomized population pharmacokinetic analysis and safety of intravenous
acetaminophen for acute postoperative pain in neonates and infants. J Clin
Pharmacol. (2019) 60:16–27. doi: 10.1002/jcph.1508
47. Flint RB, Roofthooft DW, van Rongen A, van Lingen RA, van den Anker JN,
van Dijk M, et al. Exposure to acetaminophen and all its metabolites upon 10,
15 and 20 mg/kg intravenous acetaminophen in very-preterm infants. Pediatr
Res. (2017) 82:678–84. doi: 10.1038/pr.2017.129
48. Zhu A, Benzon HA, Anderson TA. Evidence for the efficacy
of systemic opioid-sparing analgesics in pediatric surgical
populations: a systematic review. Anesth Analg. (2017) 125:1569–87.
doi: 10.1213/ANE.0000000000002434
49. Michelet D, Andreu-Gallien J, Bensalah T, Hilly J, Wood C, Nivoche
Y, et al. A meta-analysis of the use of nonsteroidal antiinflammatory
drugs for pediatric postoperative pain. Anesth Analg. (2012) 114:393–406.
doi: 10.1213/ANE.0b013e31823d0b45
50. van der Marel CD, Peters JW, Bouwmeester NJ, Jacqz-Aigrain E, van den
Anker JN, Tibboel D. Rectal acetaminophen does not reduce morphine
consumption after major surgery in young infants. Br J Anaesth. (2007)
98:372–9. doi: 10.1093/bja/ael371
51. Prins SA, Van Dijk M, Van Leeuwen P, Searle S, Anderson BJ, Tibboel D, et al.
Pharmacokinetics and analgesic effects of intravenous propacetamol vs rectal
paracetamol in children after major craniofacial surgery. Paediatr Anaesth.
(2008) 18:582–92. doi: 10.1111/j.1460-9592.2008.02619.x
52. Härmä A, Aikio O, Hallman M, Saarela T. Intravenous paracetamol decreases
requirements of morphine in very preterm infants. J Pediatr. (2016) 168:36–
40. doi: 10.1016/j.jpeds.2015.08.003
53. van Lingen RA, Quak CM, Deinum HT, van de Logt F, van Eyck J, Okken
A, et al. Effects of rectally administered paracetamol on infants delivered
by vacuum extraction. Eur J Obstet Gynecol Reprod Biol. (2001) 94:73–8.
doi: 10.1016/S0301-2115(00)00336-5
54. Tinner EM, Hoesli I, Jost K, Schöbi N, Ulrich Megged Y, Burkhardt
T, et al. Rectal paracetamol in newborn infants after assisted vaginal
delivery may increase pain response. J Pediatr. (2013) 162:62–6.
doi: 10.1016/j.jpeds.2012.06.020
55. Howard CR, Howard FM, Weitzman ML. Acetaminophen analgesia in
neonatal circumcision: the effect on pain. Pediatrics. (1994) 93:641–6.
56. Allegaert K, Naulaers G, Vanhaesebrouck S, Anderson BJ. The paracetamol
concentration-effect relation in neonates. Paediatr Anaesth. (2013) 23:45–50.
doi: 10.1111/pan.12076
57. HöckM, Brunner B, Rier V, Thöni S, Trawöger R, Geiger R, et al. Prophylactic
low-dose paracetamol administration associated with lowered rate of patent
ductus arteriosus in preterm infants - impact on outcome and pain perception.
Pediatr Neonatol. (2019) 61:84–91. doi: 10.1016/j.pedneo.2019.06.011
58. Bührer C. In newborns, oral or rectal paracetamol fails to reduce
procedural pain, whereas intravenous paracetamol reduces morphine
requirements after major surgery. Evid Based Med. (2016) 21:93.
doi: 10.1136/ebmed-2016-110400
59. Ohlsson A, Shah PS. Paracetamol (acetaminophen) for prevention or
treatment of pain in newborns. Cochrane Database Syst Rev. (2016)
10:CD011219. doi: 10.1002/14651858.CD011219.pub3
60. Shah V, Taddio A, Ohlsson A. Randomised controlled trial of paracetamol
for heel prick pain in neonates. Arch Dis Child Fetal Neonatal Ed. (1998)
79:F209–11. doi: 10.1136/fn.79.3.F209
61. Bonetto G, Salvatico E, Varela N, Cometto C, Gómez PF, Calvo B. Pain
prevention in term neonates: randomized trial for three methods. Arch Argent
Pediatr. (2008) 106:392–6. doi: 10.1590/S0325-00752008000500004
Frontiers in Pediatrics | www.frontiersin.org 10 March 2020 | Volume 8 | Article 89
Allegaert Paracetamol for Neonatal Procedural Pain Management
62. Badiee Z, Torcan N. Effects of high dose orally administered paracetamol for
heel prick pain in premature infants. Saudi Med J. (2009) 30:1450–3.
63. Foronda O, Rocha S, Grandy G. Efficacies of paracetamol and glucose in
pain reduction in newborns: a randomized, controlled and single blind study.
Pediatr Res. (2014) 75:473.
64. Kabatas EU, Dursun A, Beken S, Dili D, Zenciroglu A, Okumus¸ N. Efficacy
of single dose oral paracetamol in reducing pain during examination for
retinopathy of prematurity: a blinded randomized controlled trial. Indian J
Pediatr. (2016) 83:22–6. doi: 10.1007/s12098-015-1765-8
65. Seifi F, Peirovifar A, Gharehbaghi MM. Comparing the efficacy of oral sucrose
and acetaminophen in pain relief for ophthalmologic screening of retinopathy
of prematurity. Am J Med Sci Med. (2013) 1:24–7. doi: 10.12691/ajmsm-1-2-2
66. Manjunatha CM, Ibhanesebhor SE, Rennix C, Fisher H, Abara R. Pain control
during retinopathy of prematurity screening: double-blind, randomised,
placebo-controlled study. Infant. (2009) 51:155–8.
67. Roofthooft DWE, Simons SHP, van Lingen RA, Tibboel D, van den Anker
JN, Reiss IKH, et al. Randomized controlled trial comparing different
single doses of intravenous paracetamol for placement of peripherally
inserted central catheters in preterm infants. Neonatology. (2017) 112:150–8.
doi: 10.1159/000468975
68. Hedén L, von Essen L, LjungmanG. Effect of high-dose paracetamol on needle
procedures in children with cancer–an RCT. Acta Paediatr. (2014) 103:314–9.
doi: 10.1111/apa.12509
69. Chuang LJ, Wang SH, Ma MC, Lin CN, Chen CL, Huang MC. A modified
developmental care bundle reduces pain and stress in preterm infants
undergoing examinations for retinopathy of prematurity: a randomised
controlled trial. J Clin Nurs. (2019) 28:545–59. doi: 10.1111/jocn.14645
70. Shah V, Taddio A, McMurtry CM, Halperin SA, Noel M, Pillai Riddell R, et al.
Pharmacological and combined interventions to reduce vaccine injection pain
in children and adults: systematic review andmeta-analysis. Clin J Pain. (2015)
31(10 Suppl.):S38–63. doi: 10.1097/AJP.0000000000000281
71. Shah V, Ohlsson A. Venepuncture versus heel lance for blood sampling
in term neonates. Cochrane Database Syst Rev. (2007) 17:CD001452.
doi: 10.1002/14651858.CD001452.pub3
72. Allegaert K, Casteels I, Tibboel D. Pain management during eye
examinations for retinopathy of prematurity: what about procedural
adaptations to blunt the pain response? Acta Paediatr. (2010) 99:488–9.
doi: 10.1111/j.1651-2227.2009.01672.x
73. Huhn EA, Visca E, Vogt DR, von Felten S, Tinner Oehler EM, Bührer C, et al.
Decreased neonatal pain response after vaginal-operative delivery with Kiwi
OmniCup versus metal ventouse. BMC Pregnancy Childbirth. (2017) 17:47.
doi: 10.1186/s12884-017-1231-x
74. Allegaert K, Rayyan M, De Rijdt T, Van Beek F, Naulaers G. Hepatic tolerance
of repeated intravenous paracetamol administration in neonates. Paediatr
Anaesth. (2008) 18:388–92. doi: 10.1111/j.1460-9592.2008.02535.x
75. Allegaert K, Naulaers G. Haemodynamics of intravenous
paracetamol in neonates. Eur J Clin Pharmacol. (2010) 66:855–8.
doi: 10.1007/s00228-010-0860-z
76. Hopchet L, Kulo A, Rayyan M, Verbesselt R, Vanhole C, de Hoon JN,
et al. Does intravenous paracetamol administration affect body temperature
in neonates? Arch Dis Child. (2011) 96:301–4. doi: 10.1136/adc.2010.2
03778
77. Philippot G, Nyberg F, Gordh T, Fredriksson A, Viberg H. Short-
term exposure and long-term consequences of neonatal exposure
to 1(9)-tetrahydrocannabinol (THC) and ibuprofen in mice.
Behav Brain Res. (2016) 307:137–44. doi: 10.1016/j.bbr.2016.
04.001
78. Philippot G, Hallgren S, Gordh T, Fredriksson A, Fredriksson R, Viberg H.
A cannabinoid receptor type 1 (CB1R) agonist enhances the developmental
neurotoxicity of acetaminophen (paracetamol). Toxicol Sci. (2018) 166:203–
12. doi: 10.1093/toxsci/kfy199
79. Harding DR, Humphries SE, Whitelaw A, Marlow N, Montgomery HE.
Cognitive outcome and cyclo-oxygenase-2 gene (-765 G/C) variation in
the preterm infant. Arch Dis Child Fetal Neonatal Ed. (2007) 92:F108–12.
doi: 10.1136/adc.2006.099499
80. Mazaud-Guittot S, Nicolas Nicolaz C, Desdoits-Lethimonier C, Coiffec I,
Ben Maamar M, Balaguer P, et al. Paracetamol, aspirin, and indomethacin
induce endocrine disturbances in the human fetal testis capable of interfering
with testicular descent. J Clin Endocrinol Metab. (2013) 98:E1757–67.
doi: 10.1210/jc.2013-2531
81. Raaijmakers A, Zhang ZY, Levtchenko E, Simons SH, Cauwenberghs
N, Heuvel LPVD, et al. Ibuprofen exposure in early neonatal life
does not affect renal function in young adolescence. Arch Dis Child
Fetal Neonatal Ed. (2018) 103:F107–11. doi: 10.1136/archdischild-2017-31
2922
82. Food and Drug Administration (2019). Available online at: https://www.fda.
gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-
fda-has-reviewed-possible-risks-pain-medicine-use-during-pregnancy
83. European Medicines Agency (2019). Available online at: https://www.ema.
europa.eu/en/documents/prac-recommendation/prac-recommendations-
signals-adopted-12-15-march-2019-prac-meeting_en.pdf
84. Juujärvi S, Kallankari H, Pätsi P, Leskinen M, Saarela T, Hallman M, et al.
Follow-up study of the early, randomised paracetamol trial to preterm infants,
found on adverse reactions at the two-years corrected age. Acta Paediatr.
(2019) 108:452–8. doi: 10.1111/apa.14614
Conflict of Interest: The author declares that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Allegaert. This is an open-access article distributed under the
terms of the Creative Commons Attribution License (CC BY). The use, distribution
or reproduction in other forums is permitted, provided the original author(s) and
the copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Pediatrics | www.frontiersin.org 11 March 2020 | Volume 8 | Article 89
